Viracta Therapeutics, Inc. (VIRX) Stock Analysis
DELISTED
What happened to Viracta Therapeutics, Inc. (VIRX) stock?
Viracta Therapeutics, Inc. (VIRX) no longer trades on public markets. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Viracta Therapeutics, Inc. (VIRX). Viracta Therapeutics, Inc. is a precision oncology company focused on developing drugs for virus-associated malignancies. Their lead product, Nana-val, is in Phase II clinical trials for Epstein-Barr virus-positive lymphoma.
Last analyzed: Mar 16, 2026Viracta Therapeutics, Inc. (VIRX) Healthcare & Pipeline Overview
VIRX OTC Market Information
VIRX trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
More about this archive record
Can I still buy VIRX shares?
No. VIRX stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for VIRX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VIRX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Viracta Therapeutics, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.